Business
Biomind Labs Announces CAD $2.52 Million Private Placement Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / January 27, 2026 /Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a clinical-stage biopharmaceutical ...
About this update from Biomind Labs Inc
[{"type":"text","content":"NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES","length":84,"tagName":"p"},{"type":"text","content":"TORONTO, ON / ACCESS Newswire / January 27, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, is pleased to announce that it intends to complete a non-brokered private placement of up to 28,000,000 units of the Company (the "Units") at a price of $0.09per Unit for gross proceeds of up to C$2,520,000 (the "Offering"). Each Unit will be comprised of one common share in the capital of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of C$0.12for a period of 24months following the completion of the Offering.","length":896,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":342,"height":89,"url":"https://media.zenfs.com/en/accesswire.ca/cb7b8a7b44bb986b24b890aac7ebf5e4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xjWeV.8TeAZQdKS_QWG5Pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/cb7b8a7b44bb986b24b890aac7ebf5e4","width":342,"height":89}},"href":"https://app.accessnewswire.com/imagelibrary/d0d0c592-0435-4d43-a6cd-e08c0edeeb67/1130967/image.png?v=1","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions including all necessary regulatory approvals. Securities issued under the Offering will be subject to a statutory hold period of four months and one day from the date of issuance.","length":290,"tagName":"p"},{"type":"text","content":"The Company may also pay finder's fees to certain eligible finders in accordance with applicable securities laws and the policies of Cboe Canada.","length":149,"tagName":"p"},{"type":"text","content":"The net proceeds of the Offering are expected to be used to advance Biomind's clinical devel...